• GlycoMAb® does not affect specific antibody productivity or cell growth (in suspension in serum- and protein-free cell culture medium).

  • By genetically modifying the antibody-producing cell line with efficient and robust vectors, high increases in potency are obtained while maintaining a simple and standard production process. No new steps, reagents, equipments, personnel, costs or risks are added to the antibody production process.

  • GlycoMAb® conserves the bivalent target-binding nature of antibodies and does not use toxic, immunogenic or radioactive moieties that can lead to higher side effects, elevated production costs or complex logistics from production to administration to patients.

  • GlycoMAb® can be applied to any industrial antibody-production cell line.

  • GlycoMAb® can be applied to chimeric, humanized and fully human antibodies.

  • GlycoMAb® is protected by one issued patent (US 6,602,684) and a number of pending patent applications from three patent families.

Roche Glycart AG
Wagistrasse 10
CH- 8952 Schlieren

Fax: 043 215 10 01

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.